Vienna, June 09, 2022 (GLOBE NEWSWIRE) — The European Hematology Association (EHA) Conference published four independent studies of Voraxaze® (glucarpidase) by various investigators for inclusion in its June 2022 EHA Hybrid Congress abstract book and for publication in HemaSphere, EHA’s peer-reviewed, open access journal.
All four abstracts are the result of independent studies in Europe and the United States; three explore whether routinely giving Voraxaze® in combination with high-dose methotrexate (“planned use”) might alleviate toxicity, manage the risk to patients and help them to complete therapy.
- PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) ADMINISTRATION IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC, by Lauren Schaff, Mina Lobbous, Dean Carlow, Lisa DeAngelis, Louis Burt Nabors, and Christian Grommes, demonstrates the feasibility of planned-use Voraxaze to facilitate the outpatient administration of HD-MTX for patients with CNS lymphoma. Twenty outpatient treatments of HD-MTX with glucarpidase were administered to a total of 7 patients. Some grade 1 and grade 2 adverse events attributable or possible attributable to Voraxaze were noted. None of the patients required hospital admission during treatment. [Link to abstract]
- REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE…
